home / stock / qlgn / qlgn quote
Last: | $0.2905 |
---|---|
Change Percent: | -1.01% |
Open: | $0.3 |
Close: | $0.2905 |
High: | $0.319 |
Low: | $0.2905 |
Volume: | 9,216 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2905 | $0.3 | $0.2905 | $0.319 | $0.2905 | 9,216 | 04-26-2024 |
$0.297 | $0.297 | $0.297 | $0.319 | $0.297 | 17,611 | 04-25-2024 |
$0.3089 | $0.32 | $0.3089 | $0.32 | $0.2907 | 24,212 | 04-24-2024 |
$0.315 | $0.307 | $0.315 | $0.32 | $0.294 | 12,891 | 04-23-2024 |
$0.2953 | $0.32 | $0.2953 | $0.32 | $0.2921 | 46,658 | 04-22-2024 |
$0.318 | $0.308 | $0.318 | $0.33 | $0.2931 | 30,836 | 04-19-2024 |
$0.3117 | $0.299 | $0.3117 | $0.330001 | $0.29 | 27,122 | 04-18-2024 |
$0.2974 | $0.3 | $0.2974 | $0.3064 | $0.2831 | 47,891 | 04-17-2024 |
$0.2998 | $0.31 | $0.2998 | $0.32 | $0.291 | 187,319 | 04-16-2024 |
$0.319899 | $0.3242 | $0.319899 | $0.33 | $0.311 | 36,259 | 04-15-2024 |
$0.332 | $0.36 | $0.332 | $0.36 | $0.2946 | 63,322 | 04-12-2024 |
$0.366 | $0.388 | $0.366 | $0.388 | $0.35 | 236,929 | 04-11-2024 |
$0.38 | $0.3908 | $0.38 | $0.4 | $0.37035 | 43,277 | 04-10-2024 |
$0.3989 | $0.4 | $0.3989 | $0.4 | $0.3819 | 83,880 | 04-09-2024 |
$0.3815 | $0.391 | $0.3815 | $0.391 | $0.3687 | 39,182 | 04-08-2024 |
$0.3952 | $0.38 | $0.3952 | $0.407 | $0.36 | 64,941 | 04-05-2024 |
$0.3854 | $0.4159 | $0.3854 | $0.4159 | $0.38 | 25,977 | 04-04-2024 |
$0.419899 | $0.42 | $0.419899 | $0.441 | $0.3699 | 149,236 | 04-03-2024 |
$0.4 | $0.4123 | $0.4 | $0.445 | $0.385 | 89,072 | 04-02-2024 |
$0.394999 | $0.4095 | $0.394999 | $0.427251 | $0.39 | 19,508 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Qualigen Therapeutics Inc. Company Name:
QLGN Stock Symbol:
NASDAQ Market:
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to a...
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical No...
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, ...